Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.

Mainz Biomed (MYNZ) announced it has entered into a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA ...

With these developments, Mainz Biomed is now fully compliant with all Nasdaq continued listing standards and will maintain its listing and trading on the Nasdaq Capital Market. Mainz Biomed ...

Mainz Biomed is now in full compliance with all Nasdaq continued listing requirements and will continue to be listed and traded on The Nasdaq Capital Market. Please follow us to stay up to date ...

Bayern Munich is once again making waves in the transfer market as they consider Mainz's 24-year-old forward, Burkhardt, as a potential backup for Harry Kane. This article will delve into Bayern’s ...

BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular ...

Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple ...